61
total announcements
ANURAS.NS · 15 min delayed
Key Stats · Yahoo Finance · as of 21 Oct 2026
Market Cap
₹12,634 Cr
P/E (TTM)
72.2
P/E (Forward)
27.8
EPS (TTM)
₹15.38
52W Low
₹1,053.60
52W High
₹1,415.00
Dividend Yield
0.14%
Beta
0.13
Price / Book
3.8
Debt / Equity
41.3
Revenue (TTM)
₹2,535 Cr
Gross Margin
46.18%
Operating Margin
16.23%
Anupam Rasayan India Ltd
Anupam Rasayan India Ltd has submitted its Integrated Annual Report for the financial year 2025-26, as per Regulation 34(1) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Anupam Rasayan India Ltd
Anupam Rasayan India Ltd has submitted its Business Responsibility and Sustainability Report for the year 2025-26, as per SEBI regulations.
Anupam Rasayan India Ltd
Anupam Rasayan India Ltd has scheduled its 23rd Annual General Meeting (AGM) on September 30, 2026, to consider and adopt the Audited Standalone and Consolidated Financial Statements for the financial year ended March 31, 2026, and to declare a final dividend of INR 1.5 per Equity Share.
ANUPAM RASAYAN INDIA LIMITED
Anupam Rasayan India Limited has appointed a Deputy Chief Financial Officer.
Anupam Rasayan India Ltd
Anupam Rasayan India Ltd has approved the acquisition of 2,60,065 equity shares of Tanfac Industries Limited at Rs. 2,341 each, for an aggregate consideration of Rs. 60,88,12,165.
Anupam Rasayan India Ltd
Anupam Rasayan India Ltd has submitted newspaper advertisement clippings pertaining to Post Offer Advertisement for the Open Offer for acquisition of fully paid-up equity shares of Bliss GVS Pharma Limited.
Anupam Rasayan India Ltd
Anupam Rasayan India Ltd has received a continued credit rating from Crisil Ratings Limited on its bank facilities and non-convertible debentures. The ratings have been placed on 'Rating Watch with Developing Implications' due to the company's acquisition of a 43.3-48.2% equity stake in Bliss GVS Pharma Ltd, which may be funded through debt, equity, or internal accrual.
Anupam Rasayan India Ltd
Anupam Rasayan India Ltd has submitted the transcript of its earnings call for Q1 FY27, which saw a 36% YoY growth in consolidated total income. The company highlighted its commercialization of new products, healthy demand across key segments, and strategic initiatives such as the Jayhawk acquisition and proposed acquisition of Bliss GVS Pharma.
Anupam Rasayan India Ltd
Anupam Rasayan India Ltd's promoter, Anand Sureshbhai Desai, has created a pledge of 2,00,000 equity shares, representing 0.17% of the total share capital, to meet the shortfall in security cover for 16,000 senior, unlisted, and redeemable non-convertible debentures issued by the company.
Anupam Rasayan India Ltd
Anupam Rasayan India Ltd has submitted newspaper advertisement clippings pertaining to its unaudited financial results for the quarter ended June 30, 2026, as per Regulation 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Anupam Rasayan India Ltd
Anupam Rasayan India Ltd has made available the audio recording of its earnings call for the quarter ended June 30, 2026, on its website.
Anupam Rasayan India Ltd
Anupam Rasayan India Ltd has announced its unaudited financial results for Q1 FY27, showing a 36% growth in consolidated total revenue and a 35% growth in consolidated EBITDA, with the company adding new products and commercializing ETFA using flow chemistry.
Anupam Rasayan India Ltd
Anupam Rasayan India Ltd has announced its unaudited financial results for Q1FY27, with total revenue of Rs 6,675 Mn, up 36% YoY, and EBITDA of Rs 1,749 Mn, up 35% YoY. The company has also achieved a technological milestone by commercializing Ethyl Trifluoroacetate using flow chemistry. Additionally, it has signed a Letter of Intent with BASQUEVOLT, S.A. for the potential long-term supply of a specialty chemical product.
Anupam Rasayan India Ltd
Anupam Rasayan India Ltd has announced its unaudited financial results for the quarter ended June 30, 2026, with revenue from operations at ₹3,288.05 crore. The company's board of directors has approved the results and also appointed Mr. Ravi Desai as Chief Operating Officer.
Anupam Rasayan India Ltd
Anupam Rasayan India Ltd has appointed Mr. Ravi Desai as Chief Operating Officer, effective from August 14, 2026. Mr. Desai has over 20 years of experience in the speciality chemicals industry and has been associated with the Company since 2012.
Anupam Rasayan India Ltd
Anupam Rasayan India Ltd's board meeting held on August 14, 2026, approved unaudited financial results for the quarter ended June 30, 2026, and appointed a new Chief Operating Officer.
Anupam Rasayan India Ltd
Anupam Rasayan India Ltd has approved the allotment of 1531 equity shares under ESOP Scheme 2020, with eligible employees exercising options at INR 225 per share, resulting in a total realization of INR 344,475. The company has obtained in-principle listing approvals from BSE and NSE for a total of 13,12,795 equity shares under the ESOP scheme.
Anupam Rasayan India Ltd
Anupam Rasayan India Ltd has scheduled an earnings call on August 14, 2026, to discuss its unaudited financial results for Q1 FY27.
Anupam Rasayan India Ltd
Anupam Rasayan India Ltd has scheduled a Board Meeting on August 14, 2026, to consider and approve the Unaudited Financial Results (Standalone and Consolidated) for the quarter ended June 30, 2026.
Anupam Rasayan India Ltd
Anupam Rasayan India Ltd has submitted newspaper advertisement clippings pertaining to the Pre-Offer Advertisement and Corrigendum to the Detailed Public Statement for the Open Offer for acquisition of fully paid-up equity shares of Bliss GVS Pharma Limited.